Back

Proteomic analysis of homeopathic glutamanergic neurotoxicity and protection

Principal Investigator: Aryan Namboodiri PhD

Affiliations: Assistant Research Professor, Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences

Background: Glutamate, the major excitatory neurotransmitter in the brain, is a causative agent in neuronal damage associated with a variety of neuropathological conditions including stroke, progressive neurodegenerative diseases (such as Alzheimer’s and Parkinson’s diseases) and neuroAIDS. This damage is mediated by several classes of glutamate receptors in two major families of receptors, one associated with ionic conductance and one with metabotropic areas. The former group of receptors is associated with calcium influx as the source of the damage. There is evidence that ultra-low doses of glutamate can be neuroprotective when brain injury is occurs. Thus, there appears to be a balance between the neuroprotective and neurotoxic action of certain agents as a function of dose or concentration. Glutamate and N-acetylaspartylglutamate [NAAG] are two such agents that share this biology and are therefore worthy of more investigation. Similarly, the homeopathic remedy, Arnica Montana, also has demonstrated long-term neuroprotection in prior studies of brain injury.

Hypotheses: Neuroprotection from low and ultra-low doses of glutamate, NAAG and Arnica involves underlying quantitative and qualitative changes in brain proteins that can be determined by proteomic methods. There is a specific, non-ribosomal dipeptide synthetase enzyme in the nervous system that acts to couple N-acetylaspartate and glutamate to form NAAG and this enzyme is involved in homeopathic neuroprotective action.

Methods and materials: An in vivo rat excitotoxic-lesion model of neuronal damage using quinolinate will be used to study [via histopathological and immunohistochemical screening] what doses of the agent are effective and what degree of neuroprotection can be obtained with low dose NAAG and glutamate. The striatum will be isolated in order to identify the constituent protein pattern between study and control groups, and unknown proteins will be identified using genetic and protein databases. In addition, efforts will be made via radiolabelled substrate and rat brain homogenates to determine if NAA is conjugated to glutamate to form NAAG by a non-ribosomal enzyme system.

Anticipated results: Preliminary work suggests that both hypotheses cited will be true, and that key protein targets which are modified by low-dose neuroprotective treatments, and the enzyme responsible for the biosynthesis of NAAG will be isolated and purified sufficiently for characterization and antibody generation. The mechanism of low-dose and homeopathic agents in these processes as neuroprotectants will then be discovered.

Relationship to SIIB mission and healing: The ability to utilize a homeopathic remedy in the treatment and possible amelioration of neurological injuries would be an outstanding achievement. The implications in both peacetime and war are evident.

Publication: From Moffett, John R & Namboodiri, MA Aryan, "Tryptophan and the immune response", Immunology and Cell Biology (2003), 81, 247-265, reproduced with permission.

PDF Link


 





Funded Research